Collecting saliva samples to study MuSK myasthenia gravis
Genome Wide Association Study of Patients With Muscle Specific Kinase Myasthenia Gravis
This study is collecting saliva samples from people with MuSK myasthenia gravis to see if certain genes are linked to the condition and to help find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 7 Years to 99 Years |
| Sex | All |
| Sponsor | Myasthenia Gravis Rare Disease Network Research network |
| Locations | 1 site (Washington, District of Columbia) |
| Trial ID | NCT06259071 on ClinicalTrials.gov |
What this trial studies
The MuSK Myasthenia 1000 study aims to gather saliva samples from 1000 individuals diagnosed with MuSK myasthenia gravis to explore genetic variations linked to this condition. By analyzing these samples, researchers hope to enhance understanding of the disease's causes and identify potential biomarkers for targeted therapies. The study will utilize a genome-wide association study (GWAS) approach, conducted by Dr. Bryan Traynor at the NIH, to uncover genetic factors that contribute to MuSK myasthenia gravis. This observational study is crucial for paving the way toward new treatment options for patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a laboratory-confirmed diagnosis of MuSK myasthenia gravis who are willing to provide saliva samples.
Not a fit: Patients who are unable to provide informed consent or unwilling to participate in the sample collection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of targeted therapies for MuSK myasthenia gravis.
How similar studies have performed: Other studies utilizing genome-wide association studies have shown success in identifying genetic factors associated with various diseases, suggesting potential for this approach in MuSK myasthenia gravis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Lab test confirming diagnosis of MuSK myasthenia gravis * Willingness to provide saliva sample via mail or in person Exclusion Criteria: * Inability to provide informed consent * Unwillingness to provide lab results of elevated muscle specific kinase antibody * Unwillingness to provide saliva sample
Where this trial is running
Washington, District of Columbia
- George Washington University — Washington, District of Columbia, United States (Recruiting)
Study contacts
- Study coordinator: Gulsen Oztosun, MD
- Email: musk1000@mfa.gwu.edu
- Phone: 202-677-6109
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.